"Molecular breast imaging"

SNMMI Procedure Standard / EANM Practice Guideline for Molecular Breast Imaging with Dedicated Gamma-Cameras SNMMI Procedure Standard / EANM Practice Guideline for Molecular Breast Imaging with Dedicated Gamma-Cameras Carrie B. Hruska*1, Christinne Corion*2,3, Lioe-Fee de Geus-Oei3,4, Beatriz E. Adrada5, Amy M. Fowler6,7,8, Katie N. Hunt1, S. Cheenu Kappadath9, Patrick Pilkington10, Lenka M dedicated for breast imaging have emerged in the market. These dedicated systems, including some that employ semiconductor detectors rather than NaI scintillators, offer improved image quality over conventional scintimammography, leading to new clinical applications and unique guidelines specific to dedicated systems. The term “molecular breast imaging (MBI)” has been generally used to describe imaging

Women's perspectives of molecular breast imaging: a qualitative study. Mammography has poor sensitivity in dense breast tissue. Retrospective studies suggest that Molecular Breast Imaging (MBI), has superior diagnostic accuracy to mammography in women with very dense breast tissue. Women's perspectives of MBI are unknown, but are crucial to understanding the feasibility of, and routes

SNMMI Procedure Standard/EANM Practice Guideline for Molecular Breast Imaging with Dedicated ?-Cameras SNMMI Procedure Standard / EANM Practice Guideline for Molecular Breast Imaging with Dedicated Gamma-Cameras Carrie B. Hruska*1, Christinne Corion*2,3, Lioe-Fee de Geus-Oei3,4, Beatriz E. Adrada5, Amy M. Fowler6,7,8, Katie N. Hunt1, S. Cheenu Kappadath9, Patrick Pilkington10, Lenka M. Pereira dedicated for breast imaging have emerged in the market. These dedicated systems, including some that employ semiconductor detectors rather than NaI scintillators, offer improved image quality over conventional scintimammography, leading to new clinical applications and unique guidelines specific to dedicated systems. The term “molecular breast imaging (MBI)” has been generally used to describe imaging

Advances and Future Directions in Molecular Breast Imaging. Molecular breast imaging (MBI) using Tc-sestamibi has advanced rapidly over the past decade. Technical advances allow lower-dose, higher-resolution imaging and biopsy capability. MBI can be used for supplemental breast cancer screening with mammography for women with dense breasts, as well as to assess neoadjuvant therapy response

Supplemental screening in the dense breast: does molecular breast imaging have a role? With the passage of a 2019 US federal law directing FDA to ensure that mammography facilities provide a summary to patients categorizing their breast density and explaining how it can influence mammography accuracy, providers will increasingly be called on to discuss the options for supplemental screening

Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. High background parenchymal uptake (BPU) on molecular breast imaging (MBI) has been identified as a breast cancer risk factor. We explored the feasibility of offering a short-term intervention of low-dose oral tamoxifen to women with high BPU and examined whether this intervention

Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer. Background Staging newly diagnosed breast cancer by using dynamic contrast material-enhanced MRI is limited by access, high cost, and false-positive findings. The utility of contrast-enhanced mammography (CEM) and Tc sestamibi-based molecular breast imaging (MBI similar to that of CEM or MBI, resulting in lower positive predictive value of additional biopsies (13 of 46 [28%; 95% CI: 17%, 44%] for MRI; 14 of 27 [52%; 95% CI: 32%, 71%] for CEM; and 11 of 25 [44%; 95% CI: 24%, 65%] for MBI (overall = .01). Conclusion Contrast-enhanced mammography, molecular breast imaging, and MRI showed similar detection of all malignancies. MRI depicted more nonindex suspicious

Breast-Specific Gamma Imaging (BSGI), Molecular Breast Imaging (MBI), or scintimammography with breast-specific gamma camera Breast-Specific Gamma Imaging (BSGI), Molecular Breast Imaging (MBI), or scintimammography with breast-specific gamma camera ..

Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study. Background parenchymal uptake (BPU), which refers to the level of Tc-99m sestamibi uptake within normal fibroglandular tissue on molecular breast imaging (MBI), has been identified as a breast cancer risk factor, independent of mammographic density. Prior analyses have used

The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy The aim of the present study was to investigate the usefulness of molecular breast imaging (MBI) in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy. A consecutive series of 43 female patients

The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery To investigate the clinical utility of molecular breast imaging (MBI) in patients with proven invasive breast cancer scheduled for breast-conserving surgery (BCS). Following approval by the institutional review board and written informed consent, records of patients

Patient Acceptance of Half-dose Vs. Half-time Molecular Breast Imaging. A number of strategies have been implemented at our institution to allow reductions in the administered dose or imaging time for molecular breast imaging (MBI). In this work, we examine patient opinions of whether dose reduction or time reduction is preferred. Sixty female volunteers were randomized to undergo MBI at either

Molecular Breast Imaging using Synthetic Projections from High-Purity Germanium Detectors: A Simulation Study High-Purity Germanium (HPGe) gamma cameras are an emerging technology for Molecular Breast Imaging (MBI) due to their 2D lateral spatial resolution, depth-of-interaction (DOI) estimation, and superb energy resolution. In this simulation study, we investigate the potential imaging

Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer Molecular breast imaging (MBI) performed with Tc sestamibi has been shown to be a valuable technique for the detection of breast cancer. Alternative radiotracers such as Tc maraciclatide may offer improved uptake in breast lesions. The purpose of this study was to compare

Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study. Molecular breast imaging (MBI) is a functional test used for supplemental screening of women with mammographically dense breasts. Additionally, MBI depicts variable levels of background parenchymal uptake (BPU) within nonmalignant, dense fibroglandular tissue. We investigated whether

Background Parenchymal Uptake During Molecular Breast Imaging and Associated Clinical Factors OBJECTIVE. The purposes of this study were to describe the prevalence of background parenchymal uptake categories observed at screening molecular breast imaging (MBI) and to examine the association of background parenchymal uptake with mammographic density and other clinical factors. MATERIALS

Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts OBJECTIVE. The purpose of this study was to assess the diagnostic performance of supplemental screening molecular breast imaging (MBI) in women with mammographically dense breasts after system modifications to permit radiation dose reduction. SUBJECTS AND METHODS. A total of 1651

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in women who are at high risk for developing breast cancer.To assess the relationship of tumor size, histologic subtype and location of lesion and how it affects lesion conspicuity and sensitivity in MBI detected cancers. Primary Objective:-To compare the diagnostic performance of Molecular Breast Imaging (MBI) to breast Magnetic Resonance Imaging (MRI) in women who are at high risk of developing breast cancer.Secondary Objectives:To evaluate the sensitivity, specificity, positive predictive value (PPV